“Even if we compensate for the differences in population size, the U.S. is still miles ahead when it comes to total cardiomyopathy cases," explained Walter Gabriel, MPH, an epidemiologist and analyst on the report.

Leadless pacemaker technology is expanding its ability to treat more patients with dual-chamber pacing.

Ancora Heart received the FDA’s breakthrough device designation for its AccuCinch Ventricular Restoration System, a new minimally invasive transcatheter device designed for the treatment of heart failure.

In-hospital mortality was especially high among TAVR patients presenting with hypertrophic cardiomyopathy, according to a new analysis.

The study's authors noted that the ECG acquisition technology in these wearable devices appears to be quite effective. The automated algorithms, however, could still be improved.